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Abstract This study was performed to assess attribution of
high grade cervical intraepithelial neoplasia (HG-CIN) and
invasive cervical cancer (ICC) to human papillomavirus
(HPV) genotypes and secondarily to assess reproducibility
of HG-CIN/ICC diagnosis obtained in Poland. Formalde-
hyde fixed, paraffin embedded blocks of HG-CIN/ICC
from two distant institutions were sent to a central labora-
tory together with original histological diagnoses. Central/
expert review of histopathological specimens was per-
formed and agreement between local and central/expert
diagnoses was calculated. HPV detection and genotyping
in the samples was carried out with the use of SPF10-
LiPA25 technology. Results were analyzed for 205 HG-
CIN and 193 ICC cases with centrally confirmed diagno-
ses. Kappa coefficients and 95 % confidence intervals for
HG-CIN and ICC diagnoses were: 0.13 (0.09;0.17) and
0.19 (0.11;0.26) respectively. Cohen’s kappa coefficients
for lesions with representative number of samples ranged
from 0.01 for cervical intraepithelial neoplasia grade 2 to
0.75 for adenocarcinoma. HPV DNA was detected in 96.1
and 91.2 % of the confirmed HG-CIN and ICC specimens
respectively. HPV positive HG-CIN was most commonly
attributed to HPV types: 16 (62.8), 33 (7.8), 31 (6.6), 52
(3.7), 45 (2.6) and 58 (2.6 %). HPV positive ICC was most
commonly attributed to HPV types: 16 (72.1), 18 (10.8), 33
(5.7), 45 (3.4) and 31 (1.7 %). Reproducibility of histolog-
ical diagnosis of HG-CIN/ICC obtained in Poland generally
increases with the severity of lesion and is lowest for
cervical intraepithelial neoplasia grade 2 and highest for
adenocarcinoma. Over 80 % of ICC cases are vaccine-
preventable in Poland.
Keywords Cervicalcancer .CIN .Diagnosis reproducibility .
HPV . Poland
Introduction
Despite the long term opportunistic screening and initiation of
active organized cytological screening in 2006 [1], cervical
cancer (CC) age standardized mortality ratio of 5.8/100 000 in
Poland in 2008 is estimated almost twice as high as the
average 3.0/100 000 in the European Union [2]. Among
possible causes are: low and stable coverage rates not exceed-
ing 25 % of organized screening with unknown quality, un-
determined coverage and quality of opportunistic screening,
This manuscript reports a part of data obtained in HERACLES/SCALE
European studies and focuses on Poland. Selected methods used in our
study (protocol of sample retrieval and collection, expert pathology
review and HPV detection and genotyping) are based on these studies
first reported in [8].
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undetermined quality of triage of abnormal pap tests, the
quality of histological diagnosis, treatment and follow-up of
patients with cervical neoplasia [3].
Identification of high risk types of human papillomavi-
ruses (HR HPVs) as a necessary etiological factor of CC has
led to elaboration and implementation of effective vaccines
against HPV in many countries around the world, however
primary prevention of CC through HPV vaccination is still
not available in the Polish reimbursed immunization pro-
gram [4]. Information on HPV-type distribution in cervical
neoplasia is crucial for pharmacoeconomic modeling of
HPV vaccination impact on the epidemiology of cervical
lesions. Such comprehensive and reliable data obtained on
histological samples both of high grade cervical
intraepithelial neoplasia (HG-CIN) and invasive cervical
cancer (ICC) using standardized methodology have been
unavailable for Poland yet. Available studies were performed
on relatively small numbers of cases, cytological samples
and/or performed with the use of older diagnostic methods
[5–7].
The current study is a part of a large project which
assessed the HPV-type distribution in HG-CIN encompassing
CIN2, CIN2/3, CIN3 and adenocarcinoma in situ (AIS) and
also in invasive cervical cancer (ICC) in selected European
countries for which data were incomplete [8]. Our study has
however focused only on Poland to provide up-to-date and
detailed epidemiological information on the attribution of
HG-CIN and ICC to certain HPV-genotypes specifically in
the country.
One of the factors influencing the effectiveness of CC
prevention programs and also crucial for clinical decision-
making is the quality of histological diagnosis of cervical
neoplasia. To our knowledge, data on this issue have not
been published for Poland yet. For this reason we decided to
use data collected in the international project [8] and per-
formed a post-hoc analysis of reproducibility of HG-CIN
and ICC histological diagnosis obtained in Poland. This type
of analysis was not among the primary objectives of the
international project and was not published in the primary
paper [8].
In comparison to the primary manuscript [8], our
work provides therefore detailed information on the at-
tribution of HG-CIN/ICC to specific HPV genotypes and
completely novel data on the reproducibility of patho-
logical diagnosis in these lesions in Poland. The data
collected in this study are necessary for accurate evalu-
ation of cost-effectiveness of HPV vaccines and poten-
tially to guide the selection of HPV tests for screening
and triage of abnormal pap results in the screening
program. Information on reproducibility of histological
diagnosis of cervical neoplasia is important for imple-
mentation of quality reassurance measures in pathologi-
cal work-up.
Materials and Methods
Study Design and Materials
Our study is based on the material collected in HERACLES
and SCALE studies published recently [8] which were paral-
lel, cross-sectional, multicenter studies of HPV-type distribu-
tion in 3103 women with HG-CIN and 3162 women with
ICC, respectively, diagnosed in several European countries. In
each participating site which maintained an archive of cervical
excision tissue material, consecutive formalin-fixed paraffin-
embedded excision specimens of HG-CIN and/or ICC diag-
nosed between 2001 and 2008 were collected. According to a
standardized protocol of sample retrieval and collection, con-
secutive formalin-fixed paraffin-embedded tissue blocks from
women diagnosed with HG-CIN and ICC between 2001 and
2008 were requested from the sites. Only most recent blocks
containing the highest grade of CIN or the primary ICC
obtained before chemo/radiotherapy were selected. Patient’s
age at specimen collection, year of specimen collection and
original diagnosis at site were recorded. To be eligible for the
study, tissue blocks had to fulfill strict quality criteria [8].
Anonymized specimens were sent to the central laboratory
(DDL Diagnostic Laboratory, Rijswijk, The Netherlands) for
expert histopathological review and HPV genotyping. The
study was approved by the central and local ethics committees
and the patients (or their closest relatives if the patients were
deceased) gave written informed consent for use of the tissue
samples in the study.
Since this study focuses on HG-CIN/ICC diagnosed in
Poland, the material used was collected at two distant sites
in Poland: the First Department of Gynecology and Oncologic
Gynecology of Medical University of Lublin and the Depart-
ment of Gynecology and Oncology of the Jagiellonian Uni-
versity Medical College of Gynecology and Obstetrics in
Krakow. The two sites participate in both organized and
opportunistic cervical screening, perform triage of abnormal
pap results, carry out treatment and follow-up of women with
symptomatic and asymptomatic cervical neoplasia. Therefore
tissue samples archived at these sites should be representative
of the local population of women with cervical disease.
Histopathological Review and Laboratory Analyses
To assure the presence of lesions in the material used for HPV
genotyping, a “sandwich” method of material sectioning was
applied. The first and the last of the four 4 μm thick sections
was stained with haematoxilin and eosin (H&E) and reviewed
by an experienced gynecological pathologist blinded to the
original local diagnosis. Only if the presence and the type of
the lesion was confirmed in both H&E sections, the two
middle sections were used for DNA analysis. The highest
grade of lesion present in the sample was taken into account
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in the analysis. The sectioning was performed with strict
measures to avoid contamination [8]. Eligible sections were
tested for the presence and type of HPV using SPF10-DEIA/
LiPA25-polymerase chain reaction (PCR) system (SPF10-
LiPA25; version 1, Labo Biomedical Products, Rijswijk,
The Netherlands, based on licensed Innogenetics
technology) [8]. Total DNA was isolated through proteinase
K digestion and HPV DNAwas amplified and detected with
the use of SPF10-DEIA. In positive samples the HPV geno-
type was identified by reverse hybridization probe assay
(SPF10-LiPA25), which detects 14 high-risk (HR) (16,18,
31,33,35,39,45,51,52,56,58,59,66,68/73) and 11 low-risk
(LR) HPV types (6,11,34,40,42,43,44,53,54,70,74). If the
sample was HPVDNA negative, ten-fold DNA dilutions were
retested. All HPV-negative and a random of HG-CIN and ICC
samples were again reviewed by up to three expert patholo-
gists blinded to HPV status. Cases were classified according
to 2003 WHO classification [9]. If the diagnosis was discor-
dant, a majority decision was taken into account, if all three
expert pathologists disagreed, the case was rejected.
Statistical Analysis
Statistical methods used in this study were different to those
published in the primary manuscript [8] since no controlling
for inter-country variability was required when calculating
HPV-type distribution. Also additional analyses of reproduc-
ibility of HG-CIN/ICC diagnosis were performed since they
were among the aims of this study.
Agreement levels for each diagnosis category of cervi-
cal lesions were calculated in percent. Simple and weight-
ed kappa coefficients were calculated separately for HG-
CIN and ICC cases because study procedures and analy-
ses were done separately and cases were not transferred
between the two groups [8]. The sample size for analysis
of HPV type distribution in HG-CIN and ICC was
predefined in such a way that the precision of the 95 %
CI of the percentages would not exceed 5 % when the
percentages were lower than 10 %. Attribution of lesions
to specific HPV genotypes was calculated in HPV DNA
positive cases. In each disease category, the minimal
percentage attribution of the lesion to the HPV genotype
was calculated as the frequency of single infections of that
HPV genotype in this category of lesion. The maximal
percentage of attribution was estimated by the frequency
of single and multiple infections with the HPV genotype
considered. In addition, we computed a percentage of
proportional attribution of disease categories to HPV ge-
notypes according to a previously described method [10,
11] where a case is proportionally attributed according to
the frequency of the HPV type in the respective disease
category. Statistical analyses were performed using SAS
software (version 9.1).
Results
The flowcharts of study subjects with HG-CIN and ICC and
their samples included in the analysis are presented on Fig. 1.
Of 758 reviewed patients diagnosed with HG-CIN and 338
diagnosed with ICC between 2003 and 2008 at two study
sites, 378 and 270 respectively were recruited into the study.
Out of 378 HG-CIN specimens sent to the central laboratory,
in 163 cases the central laboratory diagnosis was discordant
with the local diagnosis of HG-CIN, 9 specimens were non-
diagnostic and diagnosis was discordant between sections
“before” and “after” the 2 middle sections planned for PCR
in one case. Out of 270 ICC specimens, in 63 cases the central
laboratory diagnosis was discordant with the local diagnosis
of ICC, 8 specimens were non-diagnostic, 5 had no laboratory
results, one had discordant diagnosis in sections “before” and
“after” sections for PCR. As a result, paraffin blocks of 205
women with HG-CIN and 193 women with ICC fulfilled all
study criteria required for inclusion into statistical analysis of
molecular testing results. There were 43 (21.0 %) CIN2, 32
(15.6 %) CIN2/3, 128 (62.4 %) CIN3, 1 (0.5 %) AIS and 1
(0.5 %) AIS + CIN3 case in the HG-CIN group and 154
(79.8 %) squamous cell carcinomas (SCC), 12 (6.2 %) ade-
nocarcinomas (ADC), 12 (6.2 %) adenosquamous carcinomas
(ASC) and 15 (7.8 %) other histological types of tumours in
the ICC group. Among 12 ADCs, there were: 10 (83.3 %)
adenocarcinomas of the endocervix (ADC-CX), 1 (8.3 %)
clear cell carcinoma (ADC-CC) and 1 (8.3 %) minimal devi-
ation carcinoma (ADC-MIN). Among 15 cases with other
histological types of cancer there were: 8 (53.3 %) cases of
undifferentiated carcinoma of the cervix (UDC), 6 (40.0 %)
microinvasive carcinomas (MIC) and 1 (6.7 %) neuroendo-
crine tumor (NEC). The median age in years (range) of wom-
en with HG-CIN was 37 (21–84) and specifically: 38 (25–84)
for CIN2, 33 (24–77) for CIN2/3, 37 (21–73) for CIN3, 48 for
AIS and 51 for AIS + HG-CIN. The median age (range) of
women with ICC was 51 (25–86) and specifically: 51 (25–74)
for SCC, 47 (40–69) for ADC, 56 (41–86) for ASC and 50
(31–80) for “other” diagnoses.
The agreement levels, simple and weighted kappa coeffi-
cients for local and central diagnoses of HG-CIN and ICC are
presented in Tables 1 and 2. Kappa coefficient values (95 %
confidence intervals) for individual diagnoses with represen-
tative numbers of cases were: 0.01 (−0.06;0.08) for CIN2,
0.36 (0.28;0.45) for CIN3, 0.20 (0.11;0.28) for SCC and 0.75
(0.56;0.93) for ADC.
HPVDNAwas detected in 197 (96.1 %) of the 205 eligible
HG-CIN and in 176 (91.2 %) of the 193 eligible ICC speci-
mens. HPV DNAwas detected in 86.0 % of CIN2, 96.9 % of
CIN2/3, 99.2 % of CIN3, 94.2 % of SCC, 83.3 % of ADC,
75.0 % of ASC and in 80.0 % of specimens with other
histological types of ICC. The two cases of AIS and AIS+
CIN3 were HPV-positive.
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Among HG-CIN and ICC, there were 80.5 and 87.6 %
samples with single HPV type respectively. In 12.7 % of HG-
CIN and in 2.1 % of ICC multiple HPV types were detected.
Undetermined HPV types were detected in 2.9 % of HG-CIN
and 1.6 % of ICC. Minimal, proportional and maximal attri-
butions of lesions to certain HPV genotypes are presented in
Table 3.
Median ages (inter-quartile ranges) of patients at the time
of histological specimen collection for women with HG-CIN
and ICC positive for DNA of HPV: 16, 18, 31, 33, 45, other
combined types and multiple types are presented at Fig. 2.
Women with ICC were older than women with HG-CIN and
the differences seem to vary with HPV genotype however p-
values are not presented as this was a post-hoc analysis
(Fig. 2).
Discussion
To our knowledge this is the first comprehensive report on
HPV prevalence and genotype distribution in almost 400 HG-
CIN and ICC tissue specimens collected consecutively at two
distant institutions in Poland and representative for local pop-
ulation of women. HPV DNAwas detected in 96.1 % of HG-
CIN and 91.2 % of ICC. HPV 16, 33, 31, 52 and 45 were
found to be most commonly causally related to the develop-
ment of HG-CIN and approximately 84 % of these lesions in
Poland can be attributed to the five listed HPV genotypes.
Low Risk HPVs (types 6, 42, 44, 53, 54) are responsible for
less than 10 % of HG-CIN in Poland. In our series they were
detected only in three CIN2 cases but absent in CIN2/3, CIN3
and ICC samples as single infections. The most frequent
Fig. 1 Flow chart of subjects with high grade cervical intraepithelial
neoplasia (HG-CIN) and invasive cervical cancer (ICC). Abbreviations:
ICC invasive cervical cancer, HG-CIN high grade cervical intraepithelial
neoplasia, SCC squamous cell carcinoma, ADC adenocarcinoma of the
cervix, ASC adenosquamous carcinoma of the cervix, CIN2 cervical
intraepithelial neoplasia grade 2, CIN2/3 cervical intraepithelial
neoplasia grade 2/3, CIN3 cervical intraepithelial neoplasia grade 3, AIS
adenocarcinoma in situ, AIS + CIN3 adenocarcinoma in situ with cervical
intraepithelial neoplasia grade 3 in one specimen. “ICC other types”
include: 8 undifferentiated carcinomas, 6 microinvasive carcinomas and
1 neuroendocrine tumour. Percentages are computed out of the total
number of subjects in the above category.
Table 1 Agreement between local and central/expert diagnosis of high grade cervical intraepithelial neoplasia
Central laboratory/Expert diagnosis
Local diagnosis Excluded1 <Eligible2 CIN2 CIN2/3 CIN3 AIS AIS + CIN3 >Eligible3 Total Agreement level (%)
CIN2 4 107 20 12 22 0 0 1 166 12.0
CIN2/3 0 3 0 1 1 0 0 0 5 20.0
CIN3 6 45 23 19 105 1 1 6 206 51.0
AIS 0 1 0 0 0 0 0 0 1 0
Data are numbers of subjects in each category; 1 includes non diagnostic samples and samples with discordant diagnosis of sections “before” and “after”
the ones sent for PCR; 2 includes: samples negative for cervical intraepithelial neoplasia, samples with cervical intraepithelial neoplasia grade 1, samples
with glandular lesions less severe than adenocarcinoma in situ; CIN2 cervical intraepithelial neoplasia grade 2, CIN2/3 cervical intraepithelial neoplasia
grade 2/3, CIN3 cervical intraepithelial neoplasia grade 3, AIS adenocarcinoma in situ, AIS + CIN3 adenocarcinoma in situ with cervical intraepithelial
neoplasia grade 3 in one specimen; 3 includes any invasive neoplasm. Simple Kappa coefficient=0.13 (0.09;0.17), weighted Kappa coefficient=− 0.01
(−0.56;0.04). For computation of Kappa coefficients, cases with central diagnoses of AIS and AIS + CIN3 were combined. Central/expert diagnosed
cases in: “Excluded”, “<Eligible”, “>Eligible” categories were combined since they had no equivalents in local diagnosis categories
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genotypes in ICCwere: HPV 16, 18, 33, 45, 31 and over 80%
of ICC in Poland can be attributed to the first two genotypes.
ICC cases were exclusively related to HR HPVs.
HPV DNA positivity rates of HG-CIN and ICC in Poland
are very similar to rates observed for HG-CIN in our analysis
of pooled European countries [8] and to rates for ICC pub-
lished by de Sanjose et al. for the World [12]. The drop in
HPV DNA positivity between tissue samples of HG-CIN and
ICC was also noted in our European analysis [8]. It may be
caused by HPV DNA integration to the host genome, degra-
dation of HPV DNA – both resulting in the loss of sequences
detected by PCR, and by other unclear factors.
HPV 16 and 33 were the most commonly found among
polish HG-CIN samples both in our study and in a previous
report by Kędzia et. al [5] but the order of the remaining
genotypes is different and direct comparisons are impossible
due to major methodological differences in design of both
studies. The order of the four most common genotypes in the
European [8] and in our series of HG-CIN specimens is the
same (HPV 16, 33, 31, 52) however HPV 45 and HPV 18
were ranked fifth in Polish and the pooled European study
respectively.
HPV 16 and 18 are universally the two most common
genotypes among ICC in our Polish, European [8] and world-
wide [12] series of samples. HPV 31, 33, 35, 45 and 52 are
reported as 3rd to 5th most common genotypes with differing
orders in our, another Polish [6], European [8] and the world-
wide [12] studies.
Restrictive analysis incorporating only minimal attribution
of ICC to HPV 16 and 18 obtained in our study reveals that
theoretically 80.7 % of ICC cases are vaccine preventable in
Poland. In the most optimistic scenario assuming maximal
attribution of ICC to HPV 16 and 18 obtained in our study and
a 50 % cross-protection of vaccines against HPV 31, 33 and
45, the rate of potentially vaccine preventable ICC cases in
Poland would be close to 90 %. The data collected in this
study are necessary for input into existing pharmacoeconomic
models and analyses before decisions of health technology
assessment regulatory agency in Poland on recommendations
of reimbursement of HPV vaccination from public funds.
Very high contribution of HPV 16 and 18 to the development
of ICC in Poland is an opportunity for effective primary
prevention of the great majority of invasive lesions. Unfortu-
nately HPV vaccines are not yet reimbursed and immuniza-
tion coverage is low.
In the light of our results indicating very frequent preva-
lence of HPV 16 and 18 among patients with ICC compared to
HG-CIN in Poland, the newest recommendations on the use of
HPV16/18 genotyping in the triage of women with atypical
squamous cells of undetermined significance (ASC-US) or no
intraepithelial lesions or malignancy (NILM) but a positive
cocktail HPV test [13] are of great importance and may have
profound clinical implications. The use of a test allowing for
distinguishing between HPV16/18 and other types could sub-
stantially help in proper identification of women with normal/
borderline cytology who require colposcopy as they are at
highest risk of existing or developing cancer.
To our knowledge, this is the first literature report of the
reproducibility of histological diagnosis of cervical neoplasia
in Poland. The quality of CIN and ICC diagnosis is important
for effective screening and treatment of cervical disease. His-
tological overdiagnosis of cervical lesions may result in over-
treatment with subsequent higher rate of complications and
adverse outcomes in the reproductive health [14]. On the other
hand, underdiagnosis may result in undertreatment with pro-
found negative outcomes, especially in cases of true invasive
lesions. Our data confirm previous reports on high inter-
observer variability in some categories of histological diagno-
sis of cervical neoplasia e.g. in CIN2 [15–17]. The level of
agreement between local and central/expert diagnosis in our
study seems to increase with the severity of cervical lesions.
Also in discordant cases, local overdiagnosis was more com-
mon than underdiagnosis. Small numbers of rarer histological
types of tumours do not allow for conclusions. The kappa
Table 2 Agreement between local and central/expert diagnosis of invasive cervical cancer
Local diagnosis Central laboratory/Expert diagnosis
Excluded1 Not eligible2 SCC ADC ASC Other types3 Total Agreement level (%)
SCC 14 58 152 0 8 14 246 61.8
ADC 0 3 0 11 2 1 17 64.7
ASC 0 1 2 1 2 0 6 33.3
UDC 0 1 0 0 0 0 1 0
Data are numbers of subjects in each category; 1 includes non diagnostic samples, samples with missing diagnosis and with discordant diagnosis of
sections “before” and “after” the ones sent for PCR; 2 includes: samples with diagnoses of noninvasive lesions, endometrioid, not otherwise specified
adenocarcinoma and other neoplasms (excluding undifferentiated, neuroendocrine and micro invasive carcinoma); SCC squamous cell carcinoma, ADC
cervical adenocarcinoma, ASC adenosquamous carcinoma, 3 includes undifferentiated, neuroendocrine and micro invasive carcinoma, UDC undiffer-
entiated carcinoma. Simple Kappa coefficient=0.19 (0.11;0.27), weighted Kappa coefficient=0.38 (0.26;0.49). For computation of Kappa coefficients,
cases with central diagnoses of “Excluded”, “Not eligible” and “Other types” were combined into one category
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coefficient was the lowest for CIN2 which is in agreement
with previous reports [15, 16] of poor reproducibility of CIN2
diagnosis which might reflect that this type of lesion does not
correspond to a well-defined phase of the pathogenic pathway
of infection and transformation of the epithelial cells [15].
Dichotomous classification of CIN: CIN1 vs CIN2+ provides
more reproducibility [15]. In our study local diagnosis of
CIN2 was changed by the central review in great majority of
samples which indicates that morphologic criteria of histolog-
ical assessment are very subjective in cases of intermediate
intraepithelial cervical pathology. We advocate the search for
accurate biomarkers to facilitate dichotomous classification of
cervical intraepithelial lesions into: 1) high probability of
spontaneous regression, 2) medium to high probability of
progression to cancer.
CIN2/3, according to WHO International Statistical Clas-
sification of the Diseases and Health Problems 10th edition
[18], is not a separate entity however it was included in the
original study protocol [8] and therefore included in our
analysis. Among the few available cases of CIN2/3, local vs
central diagnosis was fairly concordant.
Despite very low reproducibility of CIN2 and low-to-
moderate reproducibility of CIN3 between local and central
diagnosis in our study, invasive lesions were found by central/
expert pathologists only in 1 (0.6 %) case of CIN2 and 6
(2.9 %) of CIN3 cases. 64.5 % of CIN2, 60 % of CIN2/3 and
42.2 % of CIN3 lesions were downgraded by central review
which suggests a tendency to overdiagnosis and possible risk
of overtreatment of a number of patients treated at our centers.
However the most alarming finding is downgrading of almost
a quarter of local site diagnosis of SCC. It is possible that
extensive treatment protocols, overtreatment and adverse out-
comes in some patients occurred. Blinding of the tissue blocks
sent for study procedures to the central laboratory required by
the central study protocol precludes identification of the over-
treated patients. Strikingly, our results indicating possible
overtreatment of CIN and ICC as a result of histological
overdiagnosis are in contrast with epidemiological data of
relatively high mortality and case-fatality rate of women with
cervical cancer in Poland [19]. Low coverage and suboptimal
quality of organized screening and triage, subsequent diagno-
sis of many women at advanced/symptomatic stages of ICC
and suboptimal treatment are among the possible causes of the
unfavorable epidemiological situation in Poland.
Our results indirectly indicate that time of progression of
HG-CIN to ICC may vary according to HPV genotype caus-
ing the lesion (Fig. 2). However we interpret these findings
with caution being aware of cross-sectional design of the
study and limited number of samples infected with some
HPV types.
The strengths of the part of our study devoted to HPV
detection and genotyping include the use of a standardized
study protocol, consecutive collection of histological samples
representative for local populations at two distant gynecologic
oncology centers participating in all steps of national active
and opportunistic cervical screening and providing compre-
hensive diagnosis and treatment of CIN and ICC. Central
expert histopathological review of histological material from
2003 to 2008 and the use of a highly sensitive HPV genotyp-
ing method provide an up-to-date picture of the attribution of
HG-CIN and ICC to specific HPV genotypes in Poland.
The apparent drawback of our analysis, which should be
addressed in future studies, is the lack of analysis of repro-
ducibility of our local histological diagnosis of non-neoplastic
epithelium (normal, inflammatory, atrophic, reactive etc.) in
cases suspected of cervical neoplasia (e.g. based on cytology/
Fig. 2 Median age at diagnosis
of HG-CIN and ICC related to
single type and multiple type
HPV infections. Footnote: HG-
CIN high grade cervical
intraepithelial neoplasia, ICC
invasive cervical cancer. “Other”:
includes types other than:
HPV16/18/31/33/45
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colposcopy/HPV testing results) and estimation of falls-
negativity rate of our local histology. This information could
have profound clinical implications however assessment of
the quality of pathological work-up was not among the end-
points of the main protocol [8] and wewere only able to assess
reproducibility of local diagnosis of cervical neoplasia, as a
post-hoc analysis.
Nevertheless, further personnel training, improvement of
quality control measures and possibly a wider use of bio-
markers such as p16 (INK4a) and MIB-1 [20–22] could help
to increase the quality of histological diagnosis of cervical
neoplasia in Poland. HPV 16, 33 and 31 are the most common
etiological factors of HG-CIN in Poland. However in ICC,
HPV 16 and 18 are the biggest players and are together
responsible for the development of over 80 % of lesions in
Poland. This information obtained in our study is important
for future vaccination programs and HPV-based screening
protocols.
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